Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Evolent Health, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Evolent Health, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:53 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628908-26-000086
FAQ
- What is Evolent Health, Inc.'s D&A?
- Evolent Health, Inc. (EVH) reported D&A of $21.57M in Q2 2026.
- How has Evolent Health, Inc.'s D&A changed year-over-year?
- Evolent Health, Inc.'s D&A decreased by 6.8% year-over-year, from $23.14M to $21.57M.
- What is the long-term trend for Evolent Health, Inc.'s D&A?
- Over 4 years (2021 to 2025), Evolent Health, Inc.'s D&A has grown at a 17.9% compound annual growth rate (CAGR), from $60.04M to $115.85M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Evolent Health, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude